Seconda Conferenza Europea GNAO1 (2020)

1 OCTOBER 2020 | RESEARCH UPDATES SESSION

Kirill Martemyanov | Scripps Research
Insights into GNAO1 function in the brain and pathogenic mechanisms of its disease variants

Vladimir Katanaev | University of Geneva
GNAO1 encephalopathy: molecular etiology and animal models.

Simone Martinelli | Italian National Institute of Health
Modelling GNAO1-related diseases in Caenorhabditis elegans

Frank Baas | Leiden University
Gene Identification and Studies in Neurodevelopmental Disorders

Maryana Bardina | Marlin Biotech
Timofei Zatsepin | Skolkovo Institute of Science and Technology
Alexey Wolfson | Advirna
Early development of antisense oligonucleotide therapeutics to treat G203R GNAO1 encephalopathy

2 OCTOBER 2020 | CLINICIANS/RESEARCHERS ROUND TABLE

In this session clinicians and researchers who have experience with GNAO1 gene mutation will have the chance to share knowledge and ideas with each other. The aim is to establish a network of experts from all over the world and facilitate the constitution of international teams who will work together in order to better understand the neurological mechanisms underlying the disease and define the next steps to take to move the scientific research forward.

3 OCTOBER 2020 | CLINICAL/REHABILITATION SESSION

Amy Viehoever | Washington University in St. Louis
GNAO1 Natural History Study (title TBC)

Serena Galosi | Sapienza University of Rome
GNAO1 related disorders: update on clinical spectrum

Erika Axeen | University of Virginia
Preliminary results of the GNAO1 International Registry

Giovanna Zorzi | Foundation I.R.C.C.S Carlo Besta Neurological Institute
Update on treatment options in GNAO1-associated movement disorder

Alessandro Capuano | Bambino Gesù Children's Hospital
Alice Bergonzoli | Sirio Medical
Eye-tracking for communication skills assessment and training in GNAO1 patients: a single center experience

Karen Balk | Washington University in St. Louis
Occupational Therapy strategies for children affected by GNAO1 gene mutation (title TBC)

Relatori

Kirill Martemyanov
Associate Professor, Department of Metabolism & Aging Faculty
Chair of Department of Neuroscience
Scripps Research, Florida Campus

Vladimir Katanaev
Full Professor and Chair in Translational Oncology
Department of Cell Physiology and Metabolism
Translational Research Centre in Oncohaematology
Faculty of Medicine, University of Geneva

Simone Martinelli
In-staff scientist, Department of Oncology and Molecular Medicine
Istituto Superiore di Sanità (ISS)

Frank Baas
Head of Genome Diagnostics - Department of Clinical Genetics
Leiden University Medical Centre (LUMC)

Maryana Bardina
Research Fellow
Lab. of modeling and gene therapy of hereditary diseases, Group Leader
Marlin Biotech

Timofei Zatsepin
Associate Professor, Center of Life Sciences
Skolkovo Institute of Science and Technology

Alexey Wolfson
CEO Advirna

Amy Viehoever
Assistant Professor, Neurology, Washington University in St. Louis
Division of Pediatric Neurology St. Louis Children's Hospital

Serena Galosi
Department of Human Neuroscience
Sapienza Università di Roma
Umberto I - Policlinico di Roma

Erika Axeen
Pediatric neurologists
University of Virginia Medical Center

Giovanna Zorzi
U.O.C. Genetica Medica e Neurogenetica
Dipartimento di Diagnostica e Tecnologia Applicata
Fondazione IRCCS Istituto Neurologico "Carlo Besta"

Alessandro Capuano
Dipartimento di Neuroscienze e Neuroriabilitazione
Ospedale Pediatrico Bambino Gesù di Roma

Alice Bergonzoli
TNPEE - Esperta in Comunicazione Aumentativa e Alternativa
Sirio Medical

Karen Balk
Occupational Therapist
Washington University in St. Louis